| |
|
|
|
|
|
|
|||
|
Prepublished online as a Blood First Edition Paper on January 9, 2003; DOI 10.1182/blood-2002-07-2316.
PHAGOCYTES
From the New York University Medical Center, Skirball
Institute of Biomolecular Medicine, Department of Pathology, New
York.
Prostaglandin E2 (PGE2) is the
predominant eicosanoid product released by macrophages at the site of
inflammation. Binding of PGE2 to its cognate 7 transmembrane-spanning G protein-coupled receptors (GPCRs) activates
signaling pathways, leading to the synthesis of the Fos
transcription factor. Because the Ste20 serine/threonine protein kinase
(S/TPK) is a critical signal transducer for the G protein-coupled
pheromone receptor in Saccharomyces cerevisiae, we
postulated that the PGE2 GPCRs may activate one of the
Ste20 mammalian orthologs. We demonstrate here that the catalytic
activity of a hematopoietic cell-restricted, Ste20-related S/TPK,
HPK1, is positively regulated by exposure to physiological
concentrations of PGE2. Furthermore, ectopic expression
studies implicated HPK1 as a negative regulator of
PGE2-induced transcription of the fos gene. Our
data suggest that PGE2-induced activation of HPK1 may represent a novel negative regulatory pathway capable of modulating PGE2-mediated gene transcription.
(Blood. 2003;101:3687-3689) Signals generated by the prostaglandin
E2 receptors (PGE2Rs) are thought to be
propagated via the classical, well-characterized G-protein signal
transduction pathways, utilizing phospholipase B and adenylyl cyclase
as effector molecules.1 We postulate that the
PGE2Rs may activate other pathways, perhaps, engaging one
of the Ste20 family members, and utilize it to transmit or regulate the
PGE2-induced fos gene transcription.
Data presented here support our contention that exposure to
PGE2 activates HPK1 kinase activity, which, in turn,
negatively regulates PGE2-induced fos gene transcription.
Cells, antibodies, and other reagents
Molecular constructs
Transient transfections and in vitro kinase assays Jurkat T cells (1.5 × 107) were transfected as previously described.4 Whole cell lysates derived from resting or stimulated transfectants were subjected to immunoprecipitations by the indicated antibodies and were subjected to in vitro kinase reactions as described.2 Anti-HPK1 polyclonal antibody no. 7 2 was used in immunoblot assays to confirm the amounts of immunoprecipitated HPK1.Luciferase assays Jurkat cells were cotransfected with 2.5 µg of the Hu-fos-Luc reporter construct and 100 ng of pNull Renilla luciferase reporter construct along with 10 µg of the indicated experimental constructs. Dual luciferase assays were performed according to the manufacturer's direction (Promega, Madison, WI), and the relative luciferase activity was measured by the Monolight 2010 luminometer (Analytical Luminescence Laboratory, Ann Arbor, MI).
We hypothesized that the binding of PGE2 to its cognate receptors would generate signals that activate the catalytic activities of mammalian Ste20 family members. As observed in many cell types,5,6 our in vitro kinase activity screen of Ste20 orthologs revealed that most are constitutively active, and are not responsive to PGE2 stimulation, in Jurkat T cells (data not shown). However, HPK1, a hematopoietic cell-specific Ste20 family member, is robustly activated upon in vivo exposure to PGE2, in a concentration-dependent manner (Figure 1A-B). Exposure to 1 nM PGE2 induced HPK1 kinase activity. Maximum levels of kinase activity were achieved when cells were stimulated with at least 10 nM PGE2 (Figure 1A-B, lanes 4-6). The 2 lowest PGE2 concentrations that activated HPK1, 1 and 10 nM, are at physiological levels found at the sites of inflammation. It is possible that the kinase activity detected in our assay was due to a PGE2-responsive kinase that coprecipitated with HPK1. To address this concern, we transfected either the wild-type or a kinase-defective HA-HPK1 K46E mutant into Jurkat cells and stimulated the transfectants with 10 nM PGE2. The lack of kinase activity from the HA-HPK1 K46E mutant (Figure 1D-E, lanes 5-6) strengthened our conclusion that the observed kinase activities in Figure 1A-B were catalyzed by HPK1. Furthermore, using anti-HPK1 antibody, we demonstrated that endogenous
HPK1 responded to PGE2 stimulation in all hematopoietic cell lines tested (Figure 1G, lanes 1-8). Kinase activity was not
detected in the anti-HPK1 immunoprecipitates from the K562 cells, a
chronic myelogenous line that does not express HPK1 (Figure 1G, lanes
9-10). Western blot analysis using anti-HPK1 antibody confirmed that
comparable amounts of HPK1 were present in all kinase reactions (Figure
1C,F,H). Taken together, these observations established
PGE2 as a potent activator of HPK1 kinase activity in
hematopoietic cells. This is the first example of G protein-coupled receptor (GPCR) regulation of the catalytic activity of a Ste20 ortholog.
PGE2 stimulation induces c-fos gene
transcription in many cell types7,8 via a poorly
characterized cyclic adenosine monophosphate (cAMP)-independent
mechanism.9 Because Ste20 orthologs have been implicated
as critical signaling molecules in many receptor systems,10 we postulated that HPK1 might function as a
facilitator or a regulator of the PGE2-induced Fos
activation signal. To assess the effect of HPK1 on fos gene
transcription, we cotransfected either a wild-type HPK1 or the
catalytically inactive K46E mutant construct, along with a
fos promoter-regulated luciferase reporter construct, into
the Jurkat T-cell line. Consistent with findings observed in other cell
types, PGE2 treatment increased fos promoter activity by approximately 3-fold in the Jurkat T-cell line (Figure 2A). Ectopic expression of wild-type
HA-HPK1 inhibited the PGE2-induced fos promoter
activity by approximately 60% to 70%. The K46E mutant failed to
inhibit fos transcription, suggesting that the HPK1 kinase
activity is required for the inhibition of fos
transcription. This conclusion is consistent with a recent finding
that, despite its ability to activate Jun N-terminal kinase (JNK) and
c-Jun, HPK1 functions as a negative regulator of T-cell antigen
receptor (TCR)- and B-cell antigen receptor (BCR)-mediated
AP-1-dependent gene transcription.11 However, one
must be cognizant of the possibility that the observed inhibition of
fos transcription may be due to kinase activity-dependent
sequestration of critical signal transduction components by the
overexpressed HPK1. It has recently been demonstrated that
sequestration of SLP-76 family member(s) represents a possible
mechanism underlying the HPK1-mediated inhibition of TCR and BCR
signals.12 A better understanding of HPK1's role in
biologic processes awaits the development of an HPK1-deficient
animal model.
The mechanism by which PGE2Rs couple activation signals to
HPK1 is not known. While 4 PGE2R genes have been identified
(EP1 to EP4), the Gs-linked EP4 receptor is the predominant
PGE2R expressed in Jurkat T cells.13 Reverse
transcriptase-polymerase chain reaction (RT-PCR) analysis
revealed that all cell lines used in this study also express a high
level of EP4 receptor (data not shown). The EP4 receptor links
activation signals to Gs
We are grateful to Dr Joanne Pratt (Olin College, Needham, MA) for thorough reading of the manuscript. We thank Dr J. Pratt, Dr S. Baksh, Dr S. Pyarajan, and Dr Y.-J. Jin for thoughtful discussions. We are grateful to Dr F. Kiefer for providing the reagents.
Submitted July 30, 2002; accepted November 23, 2002.
Prepublished online as Blood First Edition Paper, January 9, 2003; DOI 10.1182/ blood-2002-07-2316.
Supported by National Institutes of Health, National Cancer Institute grant no. CA70758 (S.J.B.). S.S. is supported by a grant from the Association for International Cancer Research, St Andrews, Scotland.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Sansana Sawasdikosol, New York University Medical Center, Skirball Institute of Biomolecular Medicine, Department of Pathology, 540 1st Ave, 5th floor, Laboratory 1, New York, NY 10016; e-mail: sawasdik{at}saturn.med.nyu.edu.
1.
Funk CD.
Prostaglandins and leukotrienes: advances in eicosanoid biology.
Science.
2001;294:1871-1875 2. Kiefer F, Tibbles LA, Anafi M, et al. HPK1, a hematopoietic protein kinase activating the SAPK/JNK pathway. EMBO J. 1996;15:7013-7025[Abstract]. 3. Hu Q, Klippel A, Muslin AJ, Fantl WJ, Williams LT. Ras-dependent induction of cellular responses by constitutively active phosphatidylinositol-3 kinase. Science. 1995;268:100-102[Medline] [Order article via Infotrieve].
4.
Chang JH, Pratt JC, Sawasdikosol S, Kapeller R, Burakoff SJ.
The small GTP-binding protein Rho potentiates AP-1 transcription in T cells.
Mol Cell Biol.
1998;18:4986-4993 5. Pombo CM, Kehrl JH, Sanchez I, et al. Activation of the SAPK pathway by the human STE20 homologue germinal centre kinase. Nature. 1995;377:750-754[Medline] [Order article via Infotrieve].
6.
Su YC, Han J, Xu S, Cobb M, Skolnik EY.
NIK is a new Ste20-related kinase that binds NCK and MEKK1 and activates the SAPK/JNK cascade via a conserved regulatory domain.
EMBO J.
1997;16:1279-1290
7.
Danesch U, Weber PC, Sellmayer A.
Arachidonic acid increases c-fos and Egr-1 mRNA in 3T3 fibroblasts by formation of prostaglandin E2 and activation of protein kinase C.
J Biol Chem.
1994;269:27258-27263 8. Chen Y, Hughes-Fulford M. Prostaglandin E2 and the protein kinase A pathway mediate arachidonic acid induction of c-fos in human prostate cancer cells. Br J Cancer. 2000;82:2000-2006[CrossRef][Medline] [Order article via Infotrieve]. 9. Simonson MS, Herman WH, Dunn MJ. PGE2 induces c-fos expression by a cAMP-independent mechanism in glomerular mesangial cells. Exp Cell Res. 1994;215:137-144[CrossRef][Medline] [Order article via Infotrieve]. 10. Dan I, Watanabe NM, Kusumi A. The Ste20 group kinases as regulators of MAP kinase cascades. Trends Cell Biol. 2001;11:220-230[CrossRef][Medline] [Order article via Infotrieve]. 11. Liou J, Kiefer F, Dang A, et al. HPK1 is activated by lymphocyte antigen receptors and negatively regulates AP-1. Immunity. 2000;12:399-408[Medline] [Order article via Infotrieve].
12.
Yu J, Riou C, Davidson D, et al.
Synergistic regulation of immunoreceptor signaling by SLP-76-related adaptor Clnk and serine/threonine protein kinase HPK-1.
Mol Cell Biol.
2001;21:6102-6112 13. Blaschke V, Jungermann K, Puschel GP. Exclusive expression of the Gs-linked prostaglandin E2 receptor subtype 4 mRNA in mononuclear Jurkat and KM-3 cells and coexpression of subtype 4 and 2 mRNA in U-937 cells. FEBS Lett. 1996;394:39-43[CrossRef][Medline] [Order article via Infotrieve].
© 2003 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
S. Sawasdikosol, S. Pyarajan, S. Alzabin, G. Matejovic, and S. J. Burakoff Prostaglandin E2 Activates HPK1 Kinase Activity via a PKA-dependent Pathway J. Biol. Chem., November 30, 2007; 282(48): 34693 - 34699. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Zhou, J. S. Boomer, and T.-H. Tan Protein Phosphatase 4 Is a Positive Regulator of Hematopoietic Progenitor Kinase 1 J. Biol. Chem., November 19, 2004; 279(47): 49551 - 49561. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Lewitzky, M. Harkiolaki, M.-C. Domart, E. Y. Jones, and S. M. Feller Mona/Gads SH3C Binding to Hematopoietic Progenitor Kinase 1 (HPK1) Combines an Atypical SH3 Binding Motif, R/KXXK, with a Classical PXXP Motif Embedded in a Polyproline Type II (PPII) Helix J. Biol. Chem., July 2, 2004; 279(27): 28724 - 28732. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2003 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||